Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Orphazyme A/S    ORPHA   DK0060910917

ORPHAZYME A/S

(ORPHA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
01/15/2021 01/18/2021 01/19/2021 01/20/2021 01/21/2021 Date
79.9(c) 80.8(c) 84.6(c) 83(c) 84.9 Last
392 470 252 403 215 742 157 504 186 867 Volume
+2.04% +1.13% +4.70% -1.89% +2.29% Change
More quotes
Financials
Sales 2020 2,22 M 0,36 M 0,36 M
Net income 2020 -511 M -83,5 M -83,5 M
Net cash position 2020 494 M 80,8 M 80,8 M
P/E ratio 2020 -8,36x
Yield 2020 -
Sales 2021 163 M 26,7 M 26,7 M
Net income 2021 -428 M -69,9 M -69,9 M
Net cash position 2021 382 M 62,4 M 62,4 M
P/E ratio 2021 -24,1x
Yield 2021 -
Capitalization 2 880 M 468 M 471 M
EV / Sales 2020 1 073x
EV / Sales 2021 15,3x
Nbr of Employees 114
Free-Float 100%
More Financials
Company
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other... 
More about the company
Notations Surperformance© of Orphazyme A/S
Trading Rating : Investor Rating : -
More Ratings
All news about ORPHAZYME A/S
01/18Major shareholder announcement
GL
01/04Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annua..
GL
2020ORPHAZYME A/S : CytRx Issues Statement Regarding U.S. Regulatory Review of Arimo..
BU
2020Orphazyme provides regulatory update on arimoclomol for NPC
GL
2020ORPHAZYME A/S : - Bull story below Bear price
AQ
2020ORPHAZYME A/S : Kim Stratton, CEO, resigns from Orphazyme
AQ
2020Financial calendar 2021
GL
2020CYTRX : Announces Orphazyme's U.S. Expansion Ahead of Potential Regulatory Appro..
AQ
2020ORPHAZYME A/S : CytRx Announces Orphazyme's U.S. Expansion Ahead of Potential Re..
BU
2020Orphazyme establishes U.S. headquarters in Chicago as the company prepares fo..
GL
2020CYTRX : Comments on Quarterly Results and Recent Strategic Progress
AQ
2020Orphazyme A/S Seeks European Marketing Authorization for Arimoclomol for Trea..
MT
2020ORPHAZYME A/S : submits European Marketing Authorisation Application for arimocl..
AQ
2020ORPHAZYME A/S : submits European Marketing Authorisation Application for arimocl..
AQ
2020Orphazyme submits European Marketing Authorisation Application for arimoclomo..
GL
More news
News in other languages on ORPHAZYME A/S
2019ORPHAZYME A/S : flambe après des données positives en phase II/III
2018ORPHAZYME : Oddo à l'achat avant une nouvelle étude clinique
2018ORPHAZYME : Oddo confirme son conseil après la décision FDA
More news
Chart ORPHAZYME A/S
Duration : Period :
Orphazyme A/S Technical Analysis Chart | ORPHA | DK0060910917 | MarketScreener
Technical analysis trends ORPHAZYME A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 144,00 DKK
Last Close Price 83,00 DKK
Spread / Highest target 98,8%
Spread / Average Target 73,5%
Spread / Lowest Target 47,0%
EPS Revisions
Managers and Directors
NameTitle
Georges Gemayel Chairman
Anders Fink Vadsholt Chief Financial Officer
Thomas Kirkegaard Jensen Chief Scientific Officer
Thomas Blaettler Chief Medical Officer
Bo Jesper Hansen Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ORPHAZYME A/S23.70%468
GILEAD SCIENCES, INC.16.70%85 227
VERTEX PHARMACEUTICALS0.15%61 551
WUXI APPTEC CO., LTD.18.76%58 153
REGENERON PHARMACEUTICALS12.25%57 234
BEIGENE, LTD.40.41%33 081